17.88
前日終値:
$18.39
開ける:
$18.29
24時間の取引高:
233.82K
Relative Volume:
0.89
時価総額:
$366.91M
収益:
$116.88M
当期純損益:
$-25.09M
株価収益率:
-127.71
EPS:
-0.14
ネットキャッシュフロー:
$-20.74M
1週間 パフォーマンス:
-11.49%
1か月 パフォーマンス:
-17.91%
6か月 パフォーマンス:
+8.89%
1年 パフォーマンス:
+20.81%
Rigel Pharmaceuticals Stock (RIGL) Company Profile
名前
Rigel Pharmaceuticals
セクター
電話
650-624-1100
住所
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
RIGL を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RIGL
Rigel Pharmaceuticals
|
17.88 | 366.91M | 116.88M | -25.09M | -20.74M | -0.14 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-04-03 | 再開されました | Piper Sandler | Neutral |
2022-06-09 | ダウングレード | Citigroup | Buy → Neutral |
2022-06-08 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2022-06-08 | ダウングレード | Piper Sandler | Overweight → Neutral |
2022-03-23 | 開始されました | B. Riley Securities | Neutral |
2020-11-09 | ダウングレード | JP Morgan | Overweight → Neutral |
2019-11-15 | 再開されました | Cantor Fitzgerald | Overweight |
2019-09-26 | 再開されました | JP Morgan | Overweight |
2019-03-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
2018-08-27 | 開始されました | Citigroup | Buy |
2018-05-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
2017-12-21 | 再開されました | Piper Jaffray | Overweight |
2017-12-15 | 開始されました | Cantor Fitzgerald | Overweight |
2017-11-06 | 再開されました | H.C. Wainwright | Buy |
2017-03-09 | 繰り返されました | H.C. Wainwright | Buy |
2016-08-31 | 繰り返されました | H.C. Wainwright | Buy |
2016-08-30 | 繰り返されました | Piper Jaffray | Overweight |
2016-07-13 | 開始されました | H.C. Wainwright | Buy |
2016-06-13 | 開始されました | Piper Jaffray | Overweight |
2016-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
2013-04-08 | 繰り返されました | Stifel | Buy |
2012-11-29 | 開始されました | UBS | Neutral |
2012-11-06 | 繰り返されました | Oppenheimer | Outperform |
2012-03-26 | 開始されました | Canaccord Genuity | Hold |
2010-12-10 | ダウングレード | MP Advisors | Outperform → Market Perform |
すべてを表示
Rigel Pharmaceuticals (RIGL) 最新ニュース
Rigel settles patent litigation regarding its immune thrombocytopenia treatment - MSN
Rigel Pharma stock rises on patent settlement (RIGL:NASDAQ) - Seeking Alpha
Rigel, Hetero Settle Patent Suit Over Platelet-Booster Tavalisse - Bloomberg Law
Rigel climbs on blood disorder drug patent settlement - TradingView
Rigel settles patent litigation regarding its immune thrombocytopenia treatment (RIGL:NASDAQ) - Seeking Alpha
Rigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma - Nasdaq
Rigel Pharmaceuticals Settles Patent Litigation Over Tavalisse - Marketscreener.com
Rigel Pharmaceuticals resolves patent litigation related to Tavalisse - TipRanks
Rigel Announces Settlement Agreement Resolving TAVALISSE® (Fostamatinib Disodium Hexahydrate) Patent Litigation - Marketscreener.com
Rigel settles patent litigation over TAVALISSE treatment - Investing.com
Rigel Wins Patent Battle: TAVALISSE Exclusivity Protected Until 2032 in Major Settlement - StockTitan
(RIGL) Technical Pivots with Risk Controls - Stock Traders Daily
Bristol-Myers Squibb expands immuno-oncology pipeline with Flexus Biosciences, Rigel Pharmaceuticals deals - FirstWord Pharma
Rigel Pharmaceuticals appoints Mark W. Frohlich to board of directors - MSN
Statutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are - Yahoo Finance
(RIGL) Investment Analysis and Advice - Stock Traders Daily
Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook - Investing.com India
Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook By Investing.com - Investing.com South Africa
Rigel Looks Interesting, But Let's Wait For A Lower Price (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia
Rigel Pharmaceuticals adds oncology expert to board By Investing.com - Investing.com Australia
SEC Form 4 filed by Director Frohlich Mark W - Quantisnow
Rigel Pharmaceuticals appoints new board member - Investing.com
Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update - Quantisnow
Rigel Pharmaceuticals Appoints Dr. Frohlich to Board - TipRanks
Rigel appoints Mark W. Frohlich to its board -March 10, 2025 at 12:01 pm EDT - Marketscreener.com
Rigel Pharmaceuticals adds oncology expert to board - Investing.com India
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors - StockTitan
Rhumbline Advisers Has $423,000 Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
FY2025 EPS Estimates for RIGL Increased by Cantor Fitzgerald - Defense World
Citigroup Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World
Rigel Pharmaceuticals Implements 1-for-10 Reverse Stock Split: Balancing Nasdaq Compliance and Investor Appeal - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded by StockNews.com to “Buy” - Defense World
What is B. Riley’s Forecast for RIGL Q1 Earnings? - Defense World
What is HC Wainwright’s Estimate for RIGL Q1 Earnings? - Defense World
Earnings call transcript: Rigel Pharmaceuticals Q4 2024 sees strong growth By Investing.com - Investing.com Australia
Rigel Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Rigel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
B. Riley Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World
HC Wainwright Reiterates Buy Rating for Rigel Pharmaceuticals (NASDAQ:RIGL) - Defense World
What is B. Riley’s Estimate for RIGL FY2026 Earnings? - Defense World
Q3 Earnings Forecast for RIGL Issued By HC Wainwright - Defense World
Rigel Pharmaceuticals price target raised to $55 from $49 at Citi - TipRanks
Citi lifts Rigel stock price target to $55, maintains Buy rating - Investing.com
Rigel Pharmaceuticals Reports Record Sales and Strategic Growth - TipRanks
Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade - Nasdaq
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2024 Earnings Call Transcript - Insider Monkey
Rigel Pharmaceuticals stock holds Buy rating, $57 target By Investing.com - Investing.com South Africa
Rigel Pharmaceuticals stock holds Buy rating, $57 target - Investing.com India
Rigel Pharmaceuticals (RIGL) 財務データ
収益
当期純利益
現金流量
EPS
Rigel Pharmaceuticals (RIGL) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Schorno Dean L | EVP & Chief Financial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,734 |
38,020 |
57,235 |
Santos David A | EVP, Chief Commercial Officer |
Feb 04 '25 |
Sale |
20.92 |
2,125 |
44,457 |
53,500 |
Santos David A | EVP, Chief Commercial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,796 |
39,379 |
51,704 |
RODRIGUEZ RAUL R | CEO, President |
Feb 04 '25 |
Sale |
20.92 |
4,952 |
103,601 |
243,854 |
RODRIGUEZ RAUL R | CEO, President |
Feb 05 '25 |
Sale |
21.93 |
4,400 |
96,474 |
239,454 |
Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 04 '25 |
Sale |
20.92 |
1,448 |
30,294 |
40,169 |
Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 05 '25 |
Sale |
21.93 |
1,339 |
29,359 |
38,830 |
大文字化:
|
ボリューム (24 時間):